(CercleFinance.com) – Valbiotis announces the positive results of a clinical study of bioavailability and mode of action conducted on TOTUM 854 against arterial hypertension.
The results demonstrated a protective effect of TOTUM 854 on the cells of the vascular wall and a reduction in the activity of the angiotensin I converting enzyme (ACE1) in humans.
“These strong data support the potential of TOTUM 854 for lowering blood pressure from the early stages, which affects 123 million people in the United States and Europe. They are very promising for the end of the clinical development of TOTUM 854′, emphasizes the laboratory.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
